{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:42:14Z","timestamp":1792809734338,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Nutrition"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1093\/advances\/nmab060","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T20:18:57Z","timestamp":1619122737000},"page":"2265-2287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8290-9530","authenticated-orcid":false,"given":"Jikke T","family":"Boelens\u00a0Keun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse Ac","family":"Arnoldussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Vriend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4632-7418","authenticated-orcid":false,"given":"Ondine","family":"van\u00a0de\u00a0Rest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/advances\/nmab060_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson's disease","volume":"139","author":"Sveinbjornsdottir","year":"2016","journal-title":"J Neurochem"},{"issue":"S5","key":"10.1093\/advances\/nmab060_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00415-008-5004-3","article-title":"Epidemiology of Parkinson's disease","volume":"255","author":"Alves","year":"2008","journal-title":"J Neurol"},{"key":"10.1093\/advances\/nmab060_bib3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de\u00a0Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1093\/advances\/nmab060_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1124\/jpet.114.216317","article-title":"The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease","volume":"351","author":"Camargo","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"10.1093\/advances\/nmab060_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00415-010-5728-8","article-title":"Pharmacokinetics of levodopa","volume":"257","author":"Contin","year":"2010","journal-title":"J Neurol"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.410180505","article-title":"The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism","volume":"18","author":"Nutt","year":"1985","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","article-title":"Levodopa: past, present, and future","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur Neurol"},{"issue":"1468","key":"10.1093\/advances\/nmab060_bib10","first-page":"14","year":"2004","journal-title":"Inpharma Wkly"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov Disord"},{"issue":"10 Suppl","key":"10.1093\/advances\/nmab060_bib12","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"issue":"7","key":"10.1093\/advances\/nmab060_bib14","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/aian.AIAN_239_17","article-title":"Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management","volume":"20","author":"Pandey","year":"2017","journal-title":"Ann Indian Acad Neurol"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152712800672436","article-title":"Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment","volume":"11","author":"Espinoza","year":"2012","journal-title":"CNS Neurologic Disord Drug Targets"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12106","article-title":"Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis","volume":"128","author":"Hu","year":"2013","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"10.1093\/advances\/nmab060_bib18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/mds.22607","article-title":"Homocysteine levels after acute levodopa intake in patients with Parkinson's disease","volume":"24","author":"M\u00fcller","year":"2009","journal-title":"Mov Disord"},{"issue":"11","key":"10.1093\/advances\/nmab060_bib19","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00415-013-7079-8","article-title":"Levodopa, vitamins, ageing and the neuropathy of Parkinson's disease","volume":"260","author":"Rajabally","year":"2013","journal-title":"J Neurol"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib20","doi-asserted-by":"crossref","first-page":"e00698","DOI":"10.1002\/brb3.698","article-title":"Effects of levodopa\/carbidopa intestinal gel versus oral levodopa\/carbidopa on B vitamin levels and neuropathy","volume":"7","author":"Loens","year":"2017","journal-title":"Brain Behavior"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","article-title":"Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery","volume":"19","author":"M\u00fcller","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mdc3.12688","article-title":"Levodopa-induced neuropathy: a systematic review","author":"Romagnolo","year":"2019","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ana.22021","article-title":"Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease","volume":"68","author":"Toth","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib24","first-page":"75","article-title":"Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment","volume":"13","author":"G\u00fcnaydin","year":"2016","journal-title":"J Geriatr Cardiol"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.archger.2013.04.015","article-title":"Clinical significance of homocysteine (Hcy) on dementia in Parkinson's disease (PD)","volume":"57","author":"Song","year":"2013","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1093\/advances\/nmab060_bib27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neulet.2016.11.007","article-title":"Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: a meta-analysis","volume":"636","author":"Xie","year":"2017","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00223-009-9327-6","article-title":"Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease","volume":"86","author":"Lee","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1093\/advances\/nmab060_bib29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease","volume":"14","author":"Sharma","year":"2018","journal-title":"Ther Clin Risk Manage"},{"issue":"Suppl 3","key":"10.1093\/advances\/nmab060_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mds.22052","article-title":"Treatment of levodopa-induced motor complications","volume":"23","author":"Stocchi","year":"2008","journal-title":"Mov Disord"},{"issue":"6","key":"10.1093\/advances\/nmab060_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","article-title":"Entacapone in the treatment of Parkinson's disease","volume":"4","author":"Schrag","year":"2005","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1093\/advances\/nmab060_bib32","first-page":"747","article-title":"Parkinson's disease and its management: Part 4: treatment of motor complications","volume":"40","author":"DeMaagd","year":"2015","journal-title":"Pharm Ther"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5001\/omj.2011.21","article-title":"Food-drug interactions","volume":"26","author":"Bushra","year":"2011","journal-title":"Oman Med J"},{"issue":"4","key":"10.1093\/advances\/nmab060_bib34","first-page":"1","article-title":"Drug-food interactions and role of pharmacist","volume":"2","author":"Yaheya","year":"2009","journal-title":"Asian J Pharm Clin Res"},{"issue":"7","key":"10.1093\/advances\/nmab060_bib35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1212\/01.WNL.0000055899.24594.8E","article-title":"Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status","volume":"60","author":"Miller","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/WNF.0000000000000408","article-title":"Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa\/carbidopa","volume":"43","author":"Rojo-Sebasti\u00e1n","year":"2020","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib37","first-page":"148","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement","volume":"20","author":"Moher","year":"2016","journal-title":"Rev Esp Nutr Humana y Diet"},{"issue":"7829","key":"10.1093\/advances\/nmab060_bib38","first-page":"1","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.parkreldis.2003.10.004","article-title":"The effects of a normal protein diet on LevoDOPA plasma kinetics in advanced Parkinson's disease","volume":"10","author":"Simon","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1093\/advances\/nmab060_bib40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ane.12783","article-title":"Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation","volume":"136","author":"Rispoli","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib41","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.4081\/ni.2018.7737","article-title":"Treatment of levodopa induced dyskinesia with vitamin D: a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Habibi","year":"2018","journal-title":"Neurol Int"},{"issue":"9","key":"10.1093\/advances\/nmab060_bib42","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/jnnp.52.9.1063","article-title":"The effects of oral protein on the absorption of intraduodenal levodopa and motor performance","volume":"52","author":"Frankel","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1093\/advances\/nmab060_bib43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1212\/WNL.41.8.1295","article-title":"A balanced carbohydrate: protein diet in the management of Parkinson's disease","volume":"41","author":"Berry","year":"1991","journal-title":"Neurology"},{"issue":"6","key":"10.1093\/advances\/nmab060_bib44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.clnu.2014.12.007","article-title":"Amino acid supplementation in l-dopa treated Parkinson's disease patients","volume":"34","author":"Cucca","year":"2015","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib45","doi-asserted-by":"crossref","first-page":"e4382","DOI":"10.1002\/bmc.4382","article-title":"A new validated HPLC method for the determination of levodopa: application to study the impact of ketogenic diet on the pharmacokinetics of levodopa in Parkinson's participants","volume":"33","author":"Elbarbry","year":"2019","journal-title":"Biomed Chromatogr"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archneur.1992.00530260049018","article-title":"Protein redistribution diet remains effective in patients with fluctuating parkinsonism","volume":"49","author":"Karstaedt","year":"1992","journal-title":"Arch Neurol"},{"issue":"12","key":"10.1093\/advances\/nmab060_bib47","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","article-title":"Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study","volume":"66","author":"Postuma","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1093\/advances\/nmab060_bib48","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archneur.1987.00520220009006","article-title":"Dietary influences on the antiparkinsonian response to levodopa","volume":"44","author":"Juncos","year":"1987","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1093\/advances\/nmab060_bib49","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archneur.1987.00520220012007","article-title":"Plasma levels of amino acids correlate with motor fluctuations in parkinsonism","volume":"44","author":"Pincus","year":"1987","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000116649","article-title":"Protein redistribution diet and antiparkinsonian response to levodopa","volume":"31","author":"Bracco","year":"1991","journal-title":"Eur Neurol"},{"issue":"3, Part 1","key":"10.1093\/advances\/nmab060_bib51","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1212\/WNL.43.3_Part_1.611","article-title":"Aspartame use in Parkinson's disease","volume":"43","author":"Karstaedt","year":"1993","journal-title":"Neurology"},{"issue":"10","key":"10.1093\/advances\/nmab060_bib52","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/mds.21003","article-title":"Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease","volume":"21","author":"Barichella","year":"2006","journal-title":"Mov Disord"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","article-title":"Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration","volume":"12","author":"Lamberti","year":"2005","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WNF.0b013e318283fa18","article-title":"Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease","volume":"36","author":"M\u00fcller","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1093\/advances\/nmab060_bib55","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.wnf.0000150865.21759.bc","article-title":"The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson Disease","volume":"27","author":"Nagayama","year":"2004","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-199210000-00004","article-title":"Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease","volume":"15","author":"Astarloa","year":"1992","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6882-14-296","article-title":"A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters","volume":"14","author":"Fernandez-Martinez","year":"2014","journal-title":"BMC Complement Altern Med"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib58","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1212\/01.wnl.0000233916.57415.9d","article-title":"Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease","volume":"67","author":"Deleu","year":"2006","journal-title":"Neurology"},{"key":"10.1093\/advances\/nmab060_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jns.2016.01.005","article-title":"Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease\u2014in relation to the effects of Mucuna pruriens","volume":"361","author":"Nagashima","year":"2016","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib60","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/mds.22866","article-title":"Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease","volume":"25","author":"Lee","year":"2010","journal-title":"Mov Disord"},{"issue":"13","key":"10.1093\/advances\/nmab060_bib61","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/mds.23226","article-title":"Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review","volume":"25","author":"Cereda","year":"2010","journal-title":"Mov Disord"},{"issue":"206","key":"10.1093\/advances\/nmab060_bib62","first-page":"1","article-title":"Protein-restricted diets for ameliorating motor fluctuations in Parkinson's disease","volume":"9","author":"Wang","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib63","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mds.870120304","article-title":"Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease","volume":"12","author":"Nutt","year":"1997","journal-title":"Mov Disord"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.20738","article-title":"Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys","volume":"59","author":"Samadi","year":"2006","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1093\/advances\/nmab060_bib65","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.clnu.2016.06.020","article-title":"Dietary habits and neurological features of Parkinson's disease patients: implications for practice","volume":"36","author":"Barichella","year":"2017","journal-title":"Clin Nutr"},{"key":"10.1093\/advances\/nmab060_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jns.2016.05.056","article-title":"Biochemical and clinical effects of whey protein supplementation in Parkinson's disease: a pilot study","volume":"367","author":"Tosukhowong","year":"2016","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1093\/advances\/nmab060_bib67","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/mds.25585","article-title":"Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study","volume":"28","author":"Ceravolo","year":"2013","journal-title":"Mov Disord"},{"issue":"12","key":"10.1093\/advances\/nmab060_bib68","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","article-title":"Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease","volume":"19","author":"O'Suilleabhain","year":"2004","journal-title":"Mov Disord"},{"issue":"7","key":"10.1093\/advances\/nmab060_bib69","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/17425255.2011.575779","article-title":"Motor complications, levodopa metabolism and progression of Parkinson's disease","volume":"7","author":"M\u00fcller","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib70","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11011-009-9139-4","article-title":"Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease","volume":"24","author":"dos\u00a0Santos","year":"2009","journal-title":"Metab Brain Dis"},{"issue":"10","key":"10.1093\/advances\/nmab060_bib71","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/jcp.25693","article-title":"Homocysteine as a pathological biomarker for bone disease","volume":"232","author":"Behera","year":"2017","journal-title":"J Cell Physiol"},{"issue":"10","key":"10.1093\/advances\/nmab060_bib72","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1515\/CCLM.2005.194","article-title":"Homocysteine\u2014a newly recognised risk factor for osteoporosis","volume":"43","author":"Herrmann","year":"2005","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1093\/advances\/nmab060_bib73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00702-016-1519-4","article-title":"Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease","volume":"123","author":"M\u00fcller","year":"2016","journal-title":"J Neural Transm"},{"issue":"9","key":"10.1093\/advances\/nmab060_bib74","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.bbagen.2016.06.018","article-title":"L-dopa-induced hyperhomocysteinemia in Parkinson's disease: elephant in the room","volume":"1860","author":"Paul","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1093\/advances\/nmab060_bib75","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00415-011-6396-z","article-title":"Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert","volume":"259","author":"Santos-Garc\u00eda","year":"2012","journal-title":"J Neurol"},{"issue":"22","key":"10.1093\/advances\/nmab060_bib76","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1212\/WNL.0b013e31823a0ee4","article-title":"Neuropathy in Parkinson disease: prevalence and determinants","volume":"77","author":"Rajabally","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov Disord"},{"key":"10.1093\/advances\/nmab060_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/7563705","article-title":"Homocysteine levels in Parkinson's disease: is entacapone effective?","volume":"2016","author":"Kocer","year":"2016","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib79","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10072-010-0262-0","article-title":"Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients","volume":"31","author":"Nevrly","year":"2010","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.WNF.0000220817.94102.95","article-title":"The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status","volume":"29","author":"Zesiewicz","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/WNL.43.5.1036","article-title":"Oral levodopa\/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study","volume":"43","author":"Kurth","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1093\/advances\/nmab060_bib82","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.870090416","article-title":"Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa\/carbidopa","volume":"9","author":"Metman","year":"1994","journal-title":"Mov Disord"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib83","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.euroneuro.2005.01.005","article-title":"Hydrosoluble fiber (Plantago ovata husk) and levodopa I: experimental study of the pharmacokinetic interaction","volume":"15","author":"Garcia","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"10.1093\/advances\/nmab060_bib84","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euroneuro.2005.01.006","article-title":"Hydrosoluble fiber (Plantago ovata husk) and levodopa. II: Experimental study of the pharmacokinetic interaction in the presence of carbidopa","volume":"15","author":"Fernandez","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib85","first-page":"1","article-title":"Parkinson disease with constipation: clinical features and relevant factors","volume":"8","author":"Yu","year":"2018","journal-title":"Sci Rep"},{"issue":"1-2","key":"10.1093\/advances\/nmab060_bib86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","article-title":"Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease","volume":"319","author":"Doi","year":"2012","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1093\/advances\/nmab060_bib87","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.46.4.1051","article-title":"Gastric emptying in Parkinson's disease: patients with and without response fluctuations","volume":"46","author":"Djaldetti","year":"1996","journal-title":"Neurology"},{"issue":"12","key":"10.1093\/advances\/nmab060_bib88","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","article-title":"Probiotics and prebiotic fiber for constipation associated with Parkinson disease","volume":"87","author":"Barichella","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib89","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/apt.13662","article-title":"Systematic review with meta-analysis: effect of fibre supplementation on chronic idiopathic constipation in adults","volume":"44","author":"Christodoulides","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1093\/advances\/nmab060_bib90","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1152\/ajpendo.1995.269.4.E671","article-title":"Effects of caffeine on energy metabolism, heart rate, and methylxanthine metabolism in lean and obese women","volume":"269","author":"Bracco","year":"1995","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1093\/advances\/nmab060_bib91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ajcn\/49.1.44","article-title":"Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers","volume":"49","author":"Dulloo","year":"1989","journal-title":"Am J Clin Nutr"},{"key":"10.1093\/advances\/nmab060_bib92","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/mds.26459","article-title":"Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: the FRAGAMP study","volume":"30","author":"Nicoletti","year":"2015","journal-title":"Mov Disord"},{"issue":"3","key":"10.1093\/advances\/nmab060_bib93","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/mds.25319","article-title":"Caffeine consumption and risk of dyskinesia in CALM-PD","volume":"28","author":"Wills","year":"2013","journal-title":"Mov Disord"},{"issue":"2","key":"10.1093\/advances\/nmab060_bib94","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/carcin\/bgm235","article-title":"Soy isoflavones decrease the catechol-O-methyltransferase-mediated inactivation of 4-hydroxyestradiol in cultured MCF-7 cells","volume":"29","author":"Lehmann","year":"2008","journal-title":"Carcinogenesis"}],"container-title":["Advances in Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2161831322005051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2161831322005051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/advances\/article-pdf\/12\/6\/2265\/41358695\/nmab060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/advances\/article-pdf\/12\/6\/2265\/41358695\/nmab060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:03:18Z","timestamp":1761872598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2161831322005051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2161831322005051"],"URL":"https:\/\/doi.org\/10.1093\/advances\/nmab060","relation":{},"ISSN":["2161-8313"],"issn-type":[{"value":"2161-8313","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Advances in Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/advances\/nmab060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by ELSEVIERCOMPANY on behalf of American Society for Nutrition.","name":"copyright","label":"Copyright"}]}}